Introduction

Drostanolone PropionateMasteron 1002

Factory 1

musclepic 4

Products Description

Part 1: Classification Framework (By Application and Quality Grade)

To present the STROMUSC Masteron 100 systematically, the relevant products/ingredients can be broadly divided into the following categories for discussion:

1. Finished pharmaceutical grade – Pharmaceutical preparations that meet pharmacopoeial or regulatory requirements and are intended for formal clinical use or licensed production (such products will have comprehensive quality control reports, aseptic filling records, and stability studies);

2. Research/analytical grade – Pharmaceutical preparations intended for pharmaceutical research, formulation development, or in vitro/animal studies; they are fully labeled and documented but not necessarily intended for human clinical use;

3. Veterinary/industrial grade – Pharmaceutical preparations intended for specific veterinary or non-human uses; purity and impurity control standards may differ from those for pharmaceutical grade;

4. Finished oils available through market/over-the-counter channels (informal or contract packaging) – These are commonly found in the bodybuilding community or the gray market; their composition and concentration require careful identification. STROMUSC Masteron 100 is generally classified as a "finished oil preparation" (i.e., a formulation sold as a finished injectable), and is marketed and labeled as 100 mg/ml in a 10 ml bottle.

Part 2: Chemical Identity and Pharmacology

Drostanolone propionate (scientific name: drostanolone 17β-propionate, also known as dromostanolone propionate) is a 17β-esterified form of a dihydrotestosterone (DHT) derivative. Its molecular formula is typically C₂₃H₃₆O₃, with a molecular weight of approximately 360.5 g·mol⁻¹. It is well-registered and structurally annotated in chemical literature and databases. This compound is metabolized in vivo to its active form, drostanolone (after deesterification). As an androgen receptor agonist, it exhibits moderate anabolic effects and low aromatization (does not convert to estrogen). Therefore, it exhibits significant pharmacological properties: "muscle growth without edema, and beneficial for body toning." The Chemical Registration Number (CAS) is 521-12-0 in major databases.

Section 3: Physical and Chemical Properties (Related to Raw Materials and Finished Products)

1. Raw Material Powder/Crystalline Form: Drostanolone propionate is typically a crystalline solid in its pure form. Its melting point/melting range is often recorded as approximately 129–133°C in pharmaceutical monomer identification records (slight variations may occur between different monomer standards). Regarding solubility, this compound is lipophilic and readily soluble in common organic solvents (such as chloroform, ethanol, dimethyl sulfoxide, and other organic solvents). It is virtually insoluble or has very low solubility in polar aqueous phases. These properties make it more suitable for formulation in oil-based solvents for intramuscular injection.

2. Finished Oil Formulation (100 mg/ml) Properties: The finished injection consists of the active ingredient dissolved/dispersed in an appropriate proportion of an oil phase and solubilizing/stabilizing excipients, forming a clear or slightly yellow to light amber oily solution (color may vary slightly depending on the carrier oil, antioxidants, and long-term storage). Standard testing requirements include solution clarity, absence of visible suspended particles, pH (depending on the specific formulation), microbiological/sterility testing, content uniformity, and residual solvent/endotoxin testing.

Part 4: Formulations and Common Carriers (Excipients)

Common carriers and cosolvents used in the preparation of high-concentration oily injectables include: vegetable oils or medium-chain triglycerides (such as Miglyol), oleyl acetates (such as ethyl oleate), solubilizers, and preservatives (such as benzyl benzoate and benzyl alcohol). Previous pharmaceutical company or contract manufacturer formulations, patents, and standardized formulas indicate that these ingredients are frequently used in various "Masteron 100" and similarly concentrated testosterone/ester injectables to improve solubility, reduce viscosity, and ensure injection stability and sterility. Specific brand formulations (e.g., different manufacturers) will have their own carrier ratios and supplier selections, but a common approach is to use an oil-based formulation (approximately 70–90%) supplemented with approximately 2% preservatives (benzyl alcohol) and 10–20% solubility enhancers (such as benzyl benzoate) to ensure high-concentration solubility and long-term stability.

Section 5: Appearance and Color (Finished Product Description)

A qualified 100 mg/ml Masteron oil solution (10 ml) typically appears as a clear to slightly yellowish, transparent oily liquid. It is packaged in brown or clear glass vials and sealed with a rubber stopper and aluminum cap to ensure sterility and photostability. Obvious turbidity, suspended solids, dark precipitate, or an unusual odor within the vial may indicate an inhomogeneous formulation, crystallization, or improper storage, necessitating further physical, chemical, and microbiological testing. Reputable batches of finished products will include "clarity and color" criteria in the quality control report.

Part 6: Advantages and Product Selling Points (Analyzed from a Formulation and Pharmacology Perspective)

1. Enhanced Muscle Firmness and Sharpness: As a DHT derivative, drostanolone is characterized by improved muscle density and firmness and reduced water retention, which are considered advantageous for weight loss or pre-contest bodybuilding.

2. Low Estrogen-Related Side Effects: Drostanolone is not aromatized and therefore generally does not cause estrogen-dependent edema or gynecomastia.

3. Short-Acting Esters Facilitate Cycling Control: Propionate esters are relatively short-acting, resulting in faster fluctuations in blood concentrations, facilitating faster discontinuation or adjustment when needed (but also requiring more frequent dosing).

4. Convenient, Ready-to-Use Injectable Form: The finished oil formulation (100 mg/ml) eliminates the complex steps of oil preparation, making it easier to store and use in clinical and research settings (assuming it comes from a reputable source and is of controlled quality). These characteristics are all commonly marketed as "selling points" for this type of formulation. It is important to emphasize that any "advantages" must be accompanied by safety assessments and should not be used to encourage inappropriate use. ([Wikipedia][5])

Part 7 Quality Control and Identification Key Points

The identification and testing of finished products and raw materials usually include but are not limited to: visual inspection, content determination (HPLC or GC), infrared spectroscopy (IR), mass spectrometry (MS) or nuclear magnetic resonance (NMR) confirmation, melting point or refractive index determination, residual solvent detection, microbiological/sterility testing and stability testing. For pharmaceutical-grade products, batch release records, sterile filtration validation, stability studies (accelerated and long-term) and packaging integrity verification are also required. Qualified products should be accompanied by a quality certificate (COA) and an inspection report. The above inspection items are the industry's commonly used quality control checklist.

Part 8 Storage, transportation and shelf life management

The finished oil should be stored in a dry, light-proof, constant temperature environment; the commonly recommended storage temperature is room temperature to refrigeration (depending on the manufacturer's recommendations), avoiding high temperatures and repeated freezing and thawing. The packaging must be sealed, moisture-proof and marked with the production/batch number and expiration date. During transportation, avoid violent shaking and prolonged exposure to high temperatures. Long-term exposure or improper storage may cause darkening of the color, degradation of the active ingredient or precipitation.

Section 9: Safety, Risks, and Regulatory Notices

Although drostanolone propionate has historical clinical uses (e.g., past use for breast cancer treatment in some countries), as an anabolic steroid (AAS), it is strictly regulated or listed as a controlled substance in many jurisdictions. Steroid abuse carries potential risks, including endocrine disruption, cardiovascular risks, and skin and mood side effects. Injectable preparations, if sourced or prepared substandard, may also carry the risk of infection, local inflammation, or foreign body reactions. The use and disposal of these drugs should comply with local laws and regulations and consult with qualified medical or pharmaceutical professionals.

Section 10: Applicable Scenario and Limitations (Objective Statement)

This category of finished products is typically mentioned in the following situations: use as a prescription drug for a legally approved medical indication (with a doctor's order); use in pharmacological studies under controlled scientific or animal experimental conditions; and availability in the informal market for bodybuilding/bodybuilding products (such use often carries legal and health risks). Regardless of the intended use, regulatory compliance, traceability, and clinical/toxicological evidence are prioritized.

Part 11: Conclusion and Recommendations

STROMUSC Masteron 100 (Drostanolone Propionate 100 mg/ml, 10 ml) is a finished oil formulation. Its notable features include the pharmacological properties of a DHT derivative, its lipophilic physicochemical characteristics, and its oil-based finished formulation. To fully evaluate this product, in addition to focusing on its "selling points," it's also important to rigorously examine its quality control documentation, production sources, and legal compliance. When considering health-related uses, always consult a qualified medical or pharmaceutical professional and adhere to local regulatory requirements.